论文信息 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance - 字舞流文

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

A. Jakubowiak | Sharmila Patel | J. Laubach | P. Richardson | R. Orlowski | P. Voorhees | J. Kaufman | Y. Efebera | S. Holstein | D. Sborov | A. Chari | J. Vermeulen | K. Shain | A. Cowan | C. Costello | T. Wildes | L. Costa | N. Shah | R. Silbermann | H. Pei | B. Reeves | C. Rodriguez | N. Nathwani | N. Bumma | L. Anderson | T. Lin | J. B. Bartlett | A. Cortoos